Sarepta Therapeutics, Inc.
SRPT
$18.10
-$0.32-1.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -20.44% | -2.20% | 15.58% | 47.15% | 64.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.44% | -2.20% | 15.58% | 47.15% | 64.89% |
| Cost of Revenue | -12.33% | -14.54% | 93.35% | 72.71% | 82.55% |
| Gross Profit | -39.01% | 46.75% | -96.70% | 3.88% | 34.98% |
| SG&A Expenses | -22.51% | -17.26% | -11.86% | 0.30% | 8.72% |
| Depreciation & Amortization | 11.78% | 12.77% | 9.02% | -0.82% | 2.79% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.96% | -7.12% | 69.61% | 60.31% | 69.22% |
| Operating Income | -6,578.00% | 100.89% | -401.62% | -206.15% | -102.45% |
| Income Before Tax | -442.54% | 114.90% | -369.28% | -294.89% | -138.78% |
| Income Tax Expenses | -82.84% | -148.21% | -56.20% | 155.76% | 126.63% |
| Earnings from Continuing Operations | -135.91% | 126.19% | -403.27% | -322.84% | -222.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -135.91% | 126.19% | -403.27% | -322.84% | -222.54% |
| EBIT | -6,578.00% | 100.89% | -401.62% | -206.15% | -102.45% |
| EBITDA | -143.67% | 159.02% | -339.73% | -130.32% | -48.36% |
| EPS Basic | -138.13% | 126.43% | -388.23% | -311.23% | -221.51% |
| Normalized Basic EPS | -995.22% | 78.30% | -371.73% | -178.00% | -78.80% |
| EPS Diluted | -121.59% | 110.18% | -401.69% | -332.92% | -270.42% |
| Normalized Diluted EPS | -718.64% | 37.42% | -404.56% | -212.04% | -135.38% |
| Average Basic Shares Outstanding | 7.34% | 6.35% | 5.29% | 3.78% | 4.29% |
| Average Diluted Shares Outstanding | 4.72% | 6.94% | 0.45% | 4.26% | 7.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |